Target
ifosfamide
10 abstracts
Abstract
Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and de-differentiated liposarcoma (DDLPS): A single-arm phase 2 trial.Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China,
Abstract
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.Org: Hospital Sant Joan de Deu,
Abstract
Apatinib combined with ifosfamide and etoposide versus ifosfamide and etoposide in relapsed or refractory osteosarcoma (OAIE/PKUPH-sarcoma 11): A multicenter, randomized controlled trial.Org: Jiangsu Hengrui Pharmaceuticals Co, Ltd., Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University,
Abstract
A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): Feasibility and activity of concurrent chemotherapy and radiation therapy.Org: Fondazione IRCCS Istituto Nazionale dei Tumori, IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Humanitas Clinical Institute, Candiolo Cancer Institute, Centre Léon Bérard,
Abstract
Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial.Org: Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, Jinan,
Abstract
Pegylated liposomal doxorubicin combined with ifosfamide for advanced soft tissue sarcomas: A phase I dose-escalation study.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China,
Abstract
Clinical implications of recurring mutations in myxoid liposarcoma (MLS).Org: University of Texas MD Anderson Cancer Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center,
Abstract
Platelet decline rate as the indication of using recombinant human thrombopoietin to prevent chemotherapy induced thrombocytopenia: A prospective, randomized, controlled study.Org: Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Whhan, China National Biotec Group,
Abstract
Testicular GERM cell tumors treatment outcome in a national cancer institution in Peru.Org: Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru, Universidad Nacional Federico Villareal,
Abstract
Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing granulocytopenia in sarcoma patients receiving doxorubicin combined with ifosfamide: A prospective, randomized, non-inferiority phase II study.Org: Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Whhan, China, Cancer Center of Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China,